ELANE and severe congenital neutropenia: Recently, CRISPR-Cas9n-mediated gene editing to correct ELANE mutations in patient-derived hematopoietic stem cells has been explored as a potentially safe, efficient, and curative gene therapy approach for ELANE-SCN patients [48].